Tuesday, AstraZeneca Plc (NASDAQ:AZN) announced its ambitious plan to increase its total revenue to $80 billion by 2030, a significant rise from $45.8 billion in 2023.  Substantial expansion in its oncology, biopharmaceuticals, and rare disease portfolios and introducing 20 new medicines by the decade’s end will fuel the growth.  To sustain growth beyond 2030, the company will invest in transformative technologies and platforms that will shape the future of medicine. AstraZeneca will uphold its strategic focus on R&D while enhancing productivity across the organization.  This approach aims to drive operating leverage, supporting the goal of achieving a mid-30s percentage core operating margin by 2026.  The evolving portfolio ...